摘要
目的 :探讨新配方复方小檗碱治疗急、慢性腹泻的疗效。方法 :160例急、慢性腹泻病人 (男性95例 ,女性 65例 ) ,分成 2组 (每组 80例 )复方小檗碱试验组和呋喃唑酮对照组 ,分别服用复方小檗碱胶囊 0 .5g ,po ,bid ,及呋喃唑酮 0 .1g ,po ,tid ,疗程均 5～ 30d。以琼脂双倍稀释法测定复方小檗碱对福氏痢疾杆菌、致病性大肠杆菌 (EPEC)的体外抗菌活性。结果 :复方小檗碱和呋喃唑酮治疗急性腹泻的总有效率分别为 93 %和 90 % ;慢性腹泻为 85%和 35% (P <0 .0 1)。其对福氏痢疾杆菌、EPEC的MIC90 和MBC90 分别为 3.13mg·L- 1,6.2 5mg·L- 1和 2 0 0mg·L- 1,2 0 0mg·L- 1。不良反应发生率为 2%。结论 :复方小檗碱治疗急、慢性腹泻有效 ,且不良反应少。
AIM: To observe the efficacy of compound berberine in treating acute and chronic diarrhea. METHODS: (1) One hundred and sixty patients (M 95, F 65; age 46 a± s 15 a) with acute and chronic diarrhea were randomly divided into two groups (80 patients for each group). The treatment group was given compound berberine capsule one, po , bid for 5 30 d; the control group was given furazolidone 0.1 g, po , tid for 5 30 d. (2) The antibacterial activity of in vitro of bacillus dysentery and EPEC was detected by agar double dilution method on the patients treated by compound berbrine. RESULTS: The clinical efficacy rates of acute diarrhea in the treatment group and the control group were 93 % and 90 %, respectively( P >0.05; that of chronic diarrhea were 85 % and 35 %, respectively ( P < 0.01 ). To bacillus dysenteriae's MIC 90 and MBC 90 were 3.13 mg·L -1 and 200 mg·L -1 , respectively, to enteropathogenic E.Coli's MIC 90 and MBC 90 were 6.25 mg·L -1 and 200 mg·L -1 , respectively. The incidence of adverse reaction rate was 2 %. CONCLUSION: New compound berberine is effective in the treatment of acute and chronic diarrhea with mild adverse reactions.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2001年第5期360-362,共3页
Chinese Journal of New Drugs and Clinical Remedies
